Article info
Electronic pages
Correspondence
Tocilizumab for polymyalgia rheumatica: a first or second line?
- Correspondence to Professor Sergey Moiseev, Clinic of Nephrology, Internal and Occupational Diseases, Sechenov First Moscow State Medical University, Rossolimo, 11/5, Moscow 119934, Russia; clinpharm{at}mtu-net.ru
Citation
Tocilizumab for polymyalgia rheumatica: a first or second line?
Publication history
- Accepted March 23, 2016
- First published April 13, 2016.
Online issue publication
July 08, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/